CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 70% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Founded in 2003, Ypsomed Holding (YPSN) has established itself as the world’s leading producer and provider of injection and infusion systems and diabetes care products for pharmaceutical and biotech companies. Headquartered in Burgdorf, Switzerland, the Ypsomed Group operates an international network of production sites, distributors and subsidiaries. The company employs around 1,350 people. Ypsomed markets its innovative diabetes care product in more than 50 countries under the mylife Diabetescare brand. The Ypsomed Holding share price (YPSN) is set and traded on the SIX Swiss Exchange.
The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.
14:43, 2 February 2024
Read our reviews to find out more about us
Read the feedback from our clients, whatever their experience level.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.